Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5. Octet BLI competition assay using D25 and motavizumab.

Published byJoel Seppo Härkönen Modified over 4 years ago

Similar presentations

Presentation on theme: "Fig. 5. Octet BLI competition assay using D25 and motavizumab."— Presentation transcript:

1 Fig. 5. Octet BLI competition assay using D25 and motavizumab.
Octet BLI competition assay using D25 and motavizumab. (A) In a BLI assay, biosensor tips were dipped in pre-F, then into analyte, and then into competing antibody. D25 does not inhibit motavizumab binding to pre-F and vice versa, making these mAbs eligible for use in serum analysis. (B) Biosensor tips were dipped into pre-F, then into D25 or motavizumab, and then into sera. The mean percent inhibition of serum antibody binding by D25 is ~40%, and that by motavizumab is ~60%. Unlike motavizumab, there is increasing inhibition by D25 with increasing NT titers. The dashed line represents background binding inhibition. (C) A moderate correlation is found between percent binding inhibited by D25 and reciprocal EC50 NT titers, and a weak inverse correlation was found between percent binding blocked by motavizumab and NT titers. Joan O. Ngwuta et al., Sci Transl Med 2015;7:309ra162 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 5. Octet BLI competition assay using D25 and motavizumab."

Similar presentations

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Competition binding assays.

Competition binding assays.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.
Fig. 1. In vitro binding and neutralization activities of C12G6.

Fig. 1. In vitro binding and neutralization activities of C12G6.
Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.
Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.

Fig. 5. Prophylactic and therapeutic efficacy of C12G6 in ferrets.
Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.
Fig. 5. Rises in RSV PRNT during the surveillance period.

Fig. 5. Rises in RSV PRNT during the surveillance period.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.

Fig. 2 Whisker deprivation accelerates and enhances behavioral recovery after right S1FP photothrombosis. Whisker deprivation accelerates and enhances.
Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.

Fig. 2 AcPGP induces IL-8 and G-CSF release from human bronchial epithelial cells. AcPGP induces IL-8 and G-CSF release from human bronchial epithelial.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 3. Comparison of prediction performance.

Fig. 3. Comparison of prediction performance.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Similar presentations

Ads by Google